

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1-55 (canceled)

56. (currently amended) A method for ~~modulating~~ inhibiting angiogenesis in a mammal comprising administering to the mammal an effective amount of an antibody or antigen binding fragment thereof that specifically binds:

a) _____ a polypeptide comprising an amino acid sequence of SEQ ID NO:76;
and/or

b) _____ an immunogenic fragment of a protein comprising an at least ten amino acids sequence of SEQ ID NO:76 ~~to the mammal~~.

57-68. (canceled)

69. (previously presented) The method of claim 56, wherein the polypeptide is encoded by a polynucleotide comprising a nucleic acid sequence of SEQ ID NO:75.

70. (previously presented) The method of claim 56, wherein said antibody is a polyclonal, monoclonal antibody, antibody fragments, human, humanized, chimeric, bispecific or heterconjugate antibody.

71. (previously presented) The method of claim 70, wherein said antibody is an antagonist or neutralizing antibody.

72. (previously presented) The method of claim 56, wherein the antibody has polyepitopic specificity.

73. (previously presented) The method of claim 56, wherein the antibody is a human, chimeric, or humanized antibody.

74. (previously presented) The method of claim 56, wherein the antibody is an antibody fragment.

75. (previously presented) The method of claim 74, wherein the antibody fragment comprises a Fab fragment, Fab' fragment, F(ab')₂ fragment, or Fv fragment.

76. (previously presented) The method of claim 56, wherein the antibody is a heteroconjugate antibody.